EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Design and Characterization of a Multistage Peptide-Based Vaccine Platform to Target Mycobacterium tuberculosis Infection

Chiara Bellini, Emil Vergara, Fruzsina Bencs iD, Kinga Fodor, Szilvia Bősze iD, Denis Krivić, Bernadett Bacsa, Sára Eszter Surguta, József Tóvári, Rajko Reljic, Kata Horváti iD

Bioconjugate Chemistry · 2023

DOI: 10.1021/acs.bioconjchem.3c00273 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Bioconjugate Chemistry, 2023. Verfasst von Chiara Bellini und 10 weiteren Autor:innen. Beteiligte Einrichtung: MTA-TTK Lendület "Momentum" Peptide-Based Vaccines Research Group, Institute of Materials and Environmental Chemistry, Research Centre for Natural Sc…. Hauptthemen laut MEDLINE: Mycobacterium tuberculosis, Tuberculosis, Tuberculosis Vaccines. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 85 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Magyar Tudományos Akadémia, National Research, Development and Innovation Office, Austrian Science Fund.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The complex immunopathology ofMycobacterium tuberculosis(Mtb) is one of the main challenges in developing a novel vaccine against this pathogen, particularly regarding eliciting protection against both active and latent stages. Multistage vaccines, which contain antigens expressed in both phases, represent a promising strategy for addressing this issue, as testified by the tuberculosis vaccine clinical pipeline. Given this approach, we designed and characterized a multistage peptide-based vaccine platform containing CD4+ and CD8+ T cell epitopes previously validated for inducing a relevant T cell response against Mtb. After preliminary screening, CFP10 (32-39), GlfT2 (4-12), HBHA (185-194), and PPE15 (1-15) were selected as promising candidates, and we proved that the PM1 pool of these peptides triggered a T cell response in Mtb-sensitized human peripheral blood mononuclear cells (PBMCs). Taking advantage of the use of thiol-maleimide chemoselective ligation, we synthesized a multiepitope conjugate (Ac-CGHP). Our results showed a structure-activity relationship between the conjugation and a higher tendency to fold and assume an ordered secondary structure. Moreover, the palmitoylated conjugate (Pal-CGHP) comprising the same peptide antigens was associated with an enhanced cellular uptake in human and murine antigen-presenting cells and a better immunogenicity profile. Immunization study, conducted in BALB/c mice, showed that Pal-CGHP induced a significantly higher T cell proliferation and production of IFNγ and TNFα over PM1 formulated in the Sigma Adjuvant System.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Mycobacterium tuberculosisTuberculosisTuberculosis VaccinesHumansAnimalsMiceLeukocytes, MononuclearAntigens, BacterialCD4-Positive T-LymphocytesCD8-Positive T-LymphocytesEpitopes, T-LymphocytePeptides

Substanzen

Antigens, BacterialTuberculosis VaccinesEpitopes, T-LymphocytePeptides

Autor:innen und Institutionen

  • MTA-TTK Lendület "Momentum" Peptide-Based Vaccines Research Group, Institute of Materials and Environmental Chemistry, Research Centre for Natural Sciences, Budapest 1117, Hungary.
  • Hevesy György PhD School of Chemistry, Eötvös Loránd University, Budapest 1117, Hungary.
  • Institute for Infection and Immunity, St. George's, University of London, London SW17 0RE, U.K.
  • Laboratory of Structural Chemistry and Biology, Institute of Chemistry, Eötvös Loránd University, Budapest 1117, Hungary.
  • Department of Laboratory Animal Science and Animal Protection, University of Veterinary Medicine, Budapest 1078, Hungary.
  • ELKH-ELTE Research Group of Peptide Chemistry, Eötvös Loránd Research Network (ELKH), Eötvös Loránd University, Budapest 1117, Hungary.

ORCID-Profile: Fruzsina Bencs, Szilvia Bősze, Kata Horváti

Förderung

  • Magyar Tudományos Akadémia
  • National Research, Development and Innovation Office
  • Austrian Science Fund
  • H2020 Marie Sklodowska-Curie Actions
  • National Laboratories Excellence program

Zitieren

APA

Bellini, C., Vergara, E., Bencs, F., Fodor, K., Bősze, S., Krivić, D., Bacsa, B., Surguta, S. E., Tóvári, J., Reljic, R., & Horváti, K. (2023). Design and Characterization of a Multistage Peptide-Based Vaccine Platform to Target Mycobacterium tuberculosis Infection. Bioconjugate Chemistry. https://doi.org/10.1021/acs.bioconjchem.3c00273

Vancouver

Bellini C, Vergara E, Bencs F, Fodor K, Bősze S, Krivić D, et al. Design and Characterization of a Multistage Peptide-Based Vaccine Platform to Target Mycobacterium tuberculosis Infection. Bioconjugate Chemistry. 2023. doi:10.1021/acs.bioconjchem.3c00273

BibTeX
@article{Bellini2023,
  author = {Bellini, Chiara and Vergara, Emil and Bencs, Fruzsina and Fodor, Kinga and Bősze, Szilvia and Krivić, Denis and Bacsa, Bernadett and Surguta, Sára Eszter and Tóvári, József and Reljic, Rajko and Horváti, Kata},
  title = {Design and Characterization of a Multistage Peptide-Based Vaccine Platform to Target Mycobacterium tuberculosis Infection},
  journal = {Bioconjugate Chemistry},
  year = {2023},
  doi = {10.1021/acs.bioconjchem.3c00273}
}
Kostenlos starten →